Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease
- PMID: 31862486
- DOI: 10.1016/j.jhep.2019.12.008
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease
Abstract
Background & aims: Histological classifications used to diagnose/stage non-alcoholic fatty liver disease (NAFLD) are based on morphology, with undetermined clinical correlates and relevance. We assessed the clinical relevance of the fatty liver inhibition of progression (FLIP) algorithm and the steatosis, activity, and fibrosis (SAF) scoring system.
Methods: One hundred and forty consecutive patients with suspected NAFLD and a separate validation cohort of 78 patients enrolled in a therapeutic trial, all with central reading of liver biopsy, were included. FLIP and SAF were used to categorize patients with non-alcoholic steatohepatitis (NASH), non-NASH NAFLD (NAFL), or non-NAFLD. The SAF activity score assessed hepatocyte ballooning and lobular inflammation; a histologically severe disease was defined as a SAF activity score of ≥3 and/or bridging fibrosis or cirrhosis. Clinical, biochemical, and metabolic data were analyzed in relation to histology.
Results: Patients with NASH according to the FLIP algorithm had a clinical profile distinct from those with NAFL, with a higher prevalence of metabolic risk factors (increased body mass index [BMI], central obesity, serum glucose, and glycated hemoglobin), more severe insulin resistance (fasting insulin and homeostasis model assessment for insulin resistance [HOMA-IR] values), and higher levels of aminotransferases. Similar findings were documented for patients with severe disease vs. those without. Positive linear trends existed between NASH or severe disease and increasing BMI and HOMA-IR. There was a strong association between liver fibrosis and NASH or SAF-defined scores of activity. Patients with either significant or bridging fibrosis overwhelmingly had NASH, and bridging fibrosis most often coexisted with severe activity.
Conclusions: The FLIP algorithm/SAF score, although based on purely morphological grounds, are clinically relevant, as they identify patients with distinct clinical and biological profiles of disease severity. Disease activity in NAFLD is associated with fibrosis severity.
Lay summary: The examination of liver tissue under the microscope (histology) serves to define the type and severity of non-alcoholic fatty liver disease morphologically, and is also used to determine improvement in therapeutic or natural history clinical trials. The FLIP algorithm/SAF classification is a new histological classification well validated on morphological but not clinical grounds. Here, we demonstrate that different disease categories defined by the FLIP/SAF classification correspond to entities of different clinical and biological severity. We also show a strong association between the activity of steatohepatitis (defined histologically) and the amount of fibrotic scar.
Keywords: Fibrosis; Insulin resistance; Non-alcoholic steatohepatitis; SAF score.
Copyright © 2019. Published by Elsevier B.V.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Similar articles
-
Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.APMIS. 2017 Nov;125(11):962-973. doi: 10.1111/apm.12742. APMIS. 2017. PMID: 29076589
-
Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.Turk J Gastroenterol. 2019 Oct;30(10):892-898. doi: 10.5152/tjg.2019.19072. Turk J Gastroenterol. 2019. PMID: 31258138 Free PMC article.
-
Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.Ann Med. 2024 Dec;56(1):2409342. doi: 10.1080/07853890.2024.2409342. Epub 2024 Sep 30. Ann Med. 2024. PMID: 39348274 Free PMC article.
-
Clinical relevance of liver histopathology and different histological classifications of NASH in adults.Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):351-367. doi: 10.1080/17474124.2018.1415756. Epub 2017 Dec 26. Expert Rev Gastroenterol Hepatol. 2018. PMID: 29224471 Review.
-
Pathology of non-alcoholic fatty liver disease.Liver Int. 2017 Jan;37 Suppl 1:85-89. doi: 10.1111/liv.13301. Liver Int. 2017. PMID: 28052629 Review.
Cited by
-
Hepatoprotective Tetrahydrobenzocyclooctabenzofuranone Lignans from Kadsura longipedunculata.J Nat Prod. 2019 Oct 25;82(10):2842-2851. doi: 10.1021/acs.jnatprod.9b00576. Epub 2019 Sep 26. J Nat Prod. 2019. PMID: 31556297 Free PMC article.
-
Hepatic Involvement across the Metabolic Syndrome Spectrum: Non-Invasive Assessment and Risk Prediction Using Machine Learning.J Clin Med. 2023 Aug 30;12(17):5657. doi: 10.3390/jcm12175657. J Clin Med. 2023. PMID: 37685725 Free PMC article.
-
Endoplasmic Reticulum and Mitochondria Contacts Correlate with the Presence and Severity of NASH in Humans.Int J Mol Sci. 2022 Jul 28;23(15):8348. doi: 10.3390/ijms23158348. Int J Mol Sci. 2022. PMID: 35955482 Free PMC article.
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.Aliment Pharmacol Ther. 2021 Oct;54(7):952-966. doi: 10.1111/apt.16543. Epub 2021 Aug 16. Aliment Pharmacol Ther. 2021. PMID: 34398492 Free PMC article.
-
A Comparison of 13C-Methacetin and 13C-Octanoate Breath Test for the Evaluation of Nonalcoholic Steatohepatitis.J Clin Med. 2023 Mar 10;12(6):2158. doi: 10.3390/jcm12062158. J Clin Med. 2023. PMID: 36983160 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical